NAMS NewAmsterdam Pharma
- 18.820
- -0.280-1.47%
- 19.760
- +0.940+4.99%
NewAmsterdam Pharma News
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
Analysts' Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)
NewAmsterdam Pharma Company (NAMS) Receives a Buy From RBC Capital
EnGene Announces the Election of Paul Hastings and Wouter Joustra to Its Board of Directors
NewAmsterdam Pharma (NAMS.US) was first covered by TD Cowen, giving it a buy rating.
NewAmsterdam Pharma (NAMS.US) was first covered by TD Cowen, giving it a buy rating.
TD Cowen Initiates Coverage On NewAmsterdam Pharma With Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma with a Buy rating.
NewAmsterdam Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — TD Cowen Initiates Coverage On → Buy 03/14/2024 73.81% Scotiabank → $35 Initiates Coverage O
Strong Buy Rating for NewAmsterdam Pharma on Obicetrapib's Promising Efficacy and Market Potential
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Scotiabank
NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY
First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
08:04 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma 1Q Rev $1.4M >NAMS
NewAmsterdam Pharma 1Q Rev $1.4M >NAMS
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Pha
10-Q: Quarterly report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)
NewAmsterdam Pharma (NAMS.US) Announces Phase 2 Trial Results of CETP Inhibitor Under Development Effectively Reduces “Bad Cholesterol” Levels
Recently, NewAmsterdam Pharma (NAMS.US) announced the results of its phase 2 trial of the CETP inhibitor obiceTrapib at the American College of Cardiology (ACC) in 2024. Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced that Prevail for its related Phase 3 key trial has reached recruitment9
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients With Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS） today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Analysis
Price Target
No Data
